The IMI PROTECT project: purpose, organizational structure, and procedures-Reference-Cited by-同舟云学术

The IMI PROTECT project: purpose, organizational structure, and procedures

Published:2016-03 Issue: Volume:25 Page:5-10
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Reynolds Robert F.¹,Kurz Xavier²,de Groot Mark C.H.³⁴^ORCID,Schlienger Raymond G.⁵,Grimaldi-Bensouda Lamiae⁶,Tcherny-Lessenot Stephanie⁷,Klungel Olaf H.³⁸

Affiliation:

1. Epidemiology; Pfizer; New York NY USA

2. European Medicines Agency (EMA); London UK

3. Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology; Utrecht University; Utrecht the Netherlands

4. Department of Clinical Chemistry and Haematology, Division of Laboratory and Pharmacy; University Medical Center Utrecht; Utrecht the Netherlands

5. Quantitative Safety and Epidemiology; Novartis Pharma AG; Basel Switzerland

6. LA-SER and Pasteur Institute (Pharmacoepidemiology and Infectious diseases Unit); Paris France

7. Global Pharmacovigilance and Epidemiology; Sanofi; Chilly-Mazarin France

8. Julius Center for Health Sciences and Primary Care; University Medical Center Utrecht (UMCU); Utrecht the Netherlands

Funder

Innovative Medicine Initiative Joint Undertaking

European Union's Seventh Framework Programme

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference65 articles.

1. Pharmacoepidemiology: response to a challenge;Strom;Pharmacoepidemiol Drug Saf,1995

2. Pharmacoepidemiology

3. The growing role of epidemiology in drug safety regulation;Hamburg;Epidemiology,2011

4. The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women;Lewis;Am J Obstet Gynecol,1998

5. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership;Stang;Ann Intern Med,2010

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review;Pharmacoepidemiology and Drug Safety;2024-05

2. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database;Drug Safety;2022-07-12

3. Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System;Frontiers in Pharmacology;2021-12-08

4. Methodological Priorities for Patient Preferences Research: Stakeholder Input to the PREFER Public–Private Project;The Patient - Patient-Centered Outcomes Research;2021-03-15

5. Approaches for combining primary care electronic health record data from multiple sources: a systematic review of observational studies;BMJ Open;2020-10